InsidersTradesSigma
Exact Sciences CORP Stock: price and insider trades · United States · SEC (Form 4)
Track the Exact Sciences CORP share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Exact Sciences CORP has published 276 reports. Market capitalisation: €20bn. The latest transaction was reported on 30 December 2025 (Levée d'options). Among the most active insiders: Baranick Brian. All data is openly available.
276
Insider Decl.
0
Thresholds
€943,158
2 ops.
Buy Volume
€22m
53 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Exact Sciences CORP Hold (neutral), based on 10 analysts. Average price target: US$106.30.
25Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,817 of 25,936 companies
33.4
score / 100
Value27
Quality40
FCF yld·
Earn yld-0.9%
EV/EBITDA·
ROE-8.7%
Gross mgn70%
Net mgn-6.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 December 2025
Declarations276 total
3,955 shares0Common StockSEC:0001193125-25-337155:0
2,009 shares@ US$101.822.3% of flowCommon StockSEC:0001193125-25-337155:1
9,450 shares0Common StockSEC:0001193125-25-337155:2
4,799 shares@ US$101.825.4% of flowCommon StockSEC:0001193125-25-337155:3
14,845 shares0Common StockSEC:0001193125-25-337155:4
7,539 shares@ US$101.828.5% of flowCommon StockSEC:0001193125-25-337155:5
28,779 shares0Common StockSEC:0001193125-25-337155:6
14,614 shares@ US$101.8216.4% of flowCommon StockSEC:0001193125-25-337155:7
16,051 shares0Common StockSEC:0001193125-25-337155:8
8,151 shares@ US$101.829.2% of flowCommon StockSEC:0001193125-25-337155:9
42,523 shares0Common StockSEC:0001193125-25-337155:10
21,594 shares@ US$101.8224.3% of flowCommon StockSEC:0001193125-25-337155:11
20,584 shares0Common StockSEC:0001193125-25-337155:12
10,453 shares@ US$101.8211.8% of flowCommon StockSEC:0001193125-25-337155:13
29,416 shares0Common StockSEC:0001193125-25-337155:14
14,938 shares@ US$101.5916.7% of flowCommon StockSEC:0001193125-25-337155:15
38,715 shares0Common StockSEC:0001193125-25-337151:0
17,151 shares@ US$101.8261.4% of flowCommon StockSEC:0001193125-25-337151:1
24,384 shares0Common StockSEC:0001193125-25-337151:2
10,803 shares@ US$101.8238.6% of flowCommon StockSEC:0001193125-25-337151:3
363 shares@ US$38.264.8% of flowCommon StockSEC:0000950170-25-067075:0
8,527 shares0Common StockSEC:0000950170-25-061902:0
11,556 shares0Common StockSEC:0000950170-25-055422:0
66,723 shares@ US$22.386.3% of flowCommon StockSEC:0000950170-25-036484:0
3,780 shares0Common StockSEC:0000950170-25-032214:0
25 of 276 declarations
About Exact Sciences CORP
Exact Sciences Corp. is a U.S.-based company listed on the Nasdaq (EXAS) in the United States. Headquartered in Madison, Wisconsin, the company focuses on cancer screening, early detection, and precision oncology diagnostics. Founded in 1995, Exact Sciences has evolved from a niche molecular diagnostics player into one of the better-known names in oncology testing, building its franchise around non-invasive screening, clinical validation, and physician decision support. The company’s business is organized around two main pillars: Screening and Precision Oncology. In Screening, Exact Sciences is best known for Cologuard, its at-home colorectal cancer screening test, which has become the company’s flagship product and a key driver of brand recognition. More recently, the company launched Cancerguard, a multi-cancer early detection blood test available in the United States as a laboratory-developed test. In Precision Oncology, Exact Sciences markets Oncotype DX, a genomic test designed to help clinicians assess recurrence risk and guide treatment decisions in certain breast cancer settings. The portfolio is supported by ongoing clinical studies, biomarker development, and a broader innovation pipeline aimed at improving cancer detection and treatment guidance. From a competitive standpoint, Exact Sciences holds a meaningful position in the fast-growing cancer diagnostics market. Its competitive advantages include strong clinical evidence, established physician awareness, reimbursement relationships, and a recognized consumer-facing brand in colorectal screening. At the same time, the business operates in a highly competitive and regulated environment, where adoption depends on clinical utility, payer coverage, and continued evidence generation. The company’s geographic footprint remains primarily centered in the United States, although management has pointed to longer-term international opportunities. Recent developments are especially important for investors. In February 2026, Exact Sciences reported record full-year 2025 results, with revenue growth and improved cash generation. In September 2025, it launched Cancerguard in the U.S., adding a new platform in multi-cancer early detection. In November 2025, Exact Sciences announced a definitive merger agreement with Abbott Laboratories, a major strategic event that could materially change the company’s ownership structure and future operating profile. Overall, Exact Sciences looks like an innovative U.S. healthcare diagnostics company with strong exposure to the structural growth of cancer screening and precision medicine.
